Wachowiak Robin, Mayer Steffi, Kaifi Jussuf, Gebauer Florian, Izbicki Jakob R, Lacher Martin, Bockhorn Maximilian, Tachezy Michael
Department of Pediatric Surgery, University Hospital Leipzig, Leipzig, Germany
Department of Pediatric Surgery, University Hospital Leipzig, Leipzig, Germany.
Anticancer Res. 2016 Aug;36(8):3991-5.
BACKGROUND/AIM: Activated leukocyte cell adhesion molecule (ALCAM/CD166) as a member of the 'immunoglobulin superfamily' is known to be involved in cancer cell proliferation and migration. The aim of this study was to investigate the expression of ALCAM in neuroblastoma tissues.
ALCAM expression was analyzed in primary neuroblastoma specimens by immunohistochemistry on microarray sections. Histopathological and clinical data were correlated with ALCAM expression and survival analysis was performed.
Sixty-six children were included in the study. Strong expression of ALCAM was detected in 52 (79%) of the samples. Weak expression was significantly correlated with the International Neuroblastoma Staging System (INSS) stage (p=0.024) and positive n-MYC amplification (p=0.019). Recurrence-free survival (RFS) and overall survival (OS) were significantly shorter if ALCAM was expressed weakly (p=0.032 and p=0.001).
Weak ALCAM expression was significantly correlated with established markers for poor prognosis, as well as shorter RFS and OS. ALCAM might be considered as a prognostic marker for infantile neuroblastoma.
背景/目的：活化白细胞细胞黏附分子（ALCAM/CD166）作为“免疫球蛋白超家族”的一员，已知其参与癌细胞的增殖和迁移。本研究旨在调查ALCAM在神经母细胞瘤组织中的表达情况。
通过微阵列切片上的免疫组织化学分析原发性神经母细胞瘤标本中ALCAM的表达。将组织病理学和临床数据与ALCAM表达相关联，并进行生存分析。
本研究纳入66名儿童。52份（79%）样本检测到ALCAM强表达。弱表达与国际神经母细胞瘤分期系统（INSS）分期（p=0.024）及n-MYC扩增阳性（p=0.019）显著相关。如果ALCAM表达较弱，无复发生存期（RFS）和总生存期（OS）显著缩短（p=0.032和p=0.001）。
ALCAM弱表达与公认的预后不良标志物显著相关，以及较短的RFS和OS。ALCAM可被视为婴儿神经母细胞瘤的预后标志物。
